Join to View Full Profile
525 E 68th StFl 3New York, NY 10065
Phone+1 212-746-3481
Fax+1 212-746-6645
Dr. Arnason is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2007 - 2010
NYU Grossman School of MedicineResidency, Internal Medicine, 2004 - 2007
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2004
Certifications & Licensure
MA State Medical License 2010 - 2027
NY State Medical License 2007 - 2011
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL Start of enrollment: 2010 Jul 01
- Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma Start of enrollment: 2012 Mar 01
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL Start of enrollment: 2020 Oct 19
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study.Max S Topp, Matthew Matasar, John N Allan, Stephen M Ansell, Jeffrey A Barnes
Blood. 2025-04-03 - Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva
Journal of Clinical Oncology. 2025-03-01 - Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.Christine E Ryan, Yue Ren, Svitlana Tyekucheva, Jon E Arnason, Adam M Boruchov
Hemasphere. 2025-01-01
Abstracts/Posters
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisoc...Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...Jon E. Arnason, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
Tandem Meetings 2023: Research Shows Favorable Results for Lymphoma SubtypesMarch 31st, 2023- Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA to Predict Long-Term OutcomesDecember 13th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
